New Delhi, September 29, 2016: The neuroscience company Cambridge Cognition Holdings PLC (Cambridge, UK – LSE: COG), which develops and markets near patient technologies to facilitate early intervention and development of treatments for neurological disorders, today announced that it has secured the first contract for CANTAB Recruit with one of the world’s largest biotechnology companies.
This recently launched online patient recruitment product accelerates the identification of qualified clinical trial participants in high-need neurological indications.
Patient recruitment alone amounts to one third of total trial costs1with 80% of development programmes being delayed due to unfulfilled enrolment numbers2. By remotely pre-screening subjects using proprietary CANTAB® cognitive assessment, Recruit is expected to significantly reduce the cost and time of recruitment for drug development companies.
This first partnership will use CANTAB Recruit to support patient enrolment in a late-phase Alzheimer’s disease trial, helping to accelerate the development of a new drug treatment.
The commercialisation of CANTAB Recruit represents a significant milestone for Cambridge Cognition in the Company’s provision of end-to-end neurocognitive services for corporate partners to accelerate the development of optimal treatments from proof of concept studies to post-marketing.
Steven Powell, PhD, Chief Executive Officer, Cambridge Cognition: “As pharmaceutical development moves towards preventative medicine, our customers and partners face a growing challenge to find suitable subjects with neurological disease in the early stages of cognitive decline. CANTAB Recruit will enrich recruitment practices by reducing on-site screen failure rates, saving sponsors substantial time and cost. With the number of drug development programmes in Alzheimer’s disease increasing, we forecast that CANTAB Recruit will lead to significant opportunities beyond this initial contract for the Company and its partners.”
Corporate Comm India(CCI Newswire)
